Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients

Li, Sha; Wang, Lu; Yue, Meng; Chang, Yanli; Xu, Jianjun; Zhang, Qingyun

doi:10.18632/oncotarget.17176

Cited by 39 publications

(39 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We tested LAPTM4B and miR‐132‐3p mRNA levels in breast cell lines by qPCR. Compared to MCF‐10A, MDA‐MB‐231 showed the lowest miR‐132‐3p expression level, and T47D showed the highest levels (Figure A); however, LAPTM4B expression was highest in MDA‐MB‐231 and lowest in T47D (Figure A), and the LAPTM4B protein level corresponded to its expression at the mRNA level in these breast cancer cells . In breast cancer tissues and matched adjacent normal tissues, LAPTM4B mRNA level was detected by TaqMan quantitative real‐time PCR.…”

Section: Resultsmentioning

confidence: 98%

“…Compared to MCF-10A, MDA-MB-231 showed the lowest miR-132-3p expression level, and T47D showed the highest levels ( Figure 2A); however, LAPTM4B expression was highest in MDA-MB-231 and lowest in T47D ( Figure 4A), and the LAPTM4B protein level corresponded to its expression at the mRNA level in these breast cancer cells. 24 In breast cancer tissues and matched adjacent normal tissues, LAPTM4B mRNA level was detected by TaqMan quantitative real-time PCR. We found that LAPTM4B expression was significantly elevated in breast cancer specimens (8.790, 3.135-14.267, expressed as the median and quartile) ( Figure S1J).…”

Section: Correlation Between Laptm4b and Mir-132-3p Expression In Bmentioning

confidence: 99%

See 1 more Smart Citation

MicroRNA‐132‐3p inhibits tumor malignant progression by regulating lysosomal‐associated protein transmembrane 4 beta in breast cancer

Zhang

2019

Cancer Science

Self Cite

View full text Add to dashboard Cite

Lysosomal‐associated protein transmembrane 4 beta (LAPTM4B), a proto‐oncogene, has been shown to be a positive modulator in cancer progression. However, the mechanism of LAPTM4B regulation is not fully elucidated. Aberrant microRNAs (miRNAs) can regulate gene expression by interfering with target transcripts and/or translation to exert tumor‐suppressive or oncogenic effects in breast cancer. In the present study, miR‐132‐3p, which was predicted by relevant software, was confirmed to directly bind to the 3′ untranslated region (3′UTR) of LAPTM4B and negatively regulate its expression in luciferase reporter and western blot assays. Subsequently, we validated that miR‐132‐3p was downregulated in breast cancer tissues. Receiver‐operating characteristic curve analysis indicated that miR‐132‐3p had accurate diagnostic value, and a Kaplan‐Meier and Cox regression model showed that miR‐132‐3p was a potential prognostic marker for recurrence, showing low levels in breast cancer patients. In addition, we showed that miR‐132‐3p was inversely correlated with LAPTM4B expression in the above samples. Functionally, miR‐132‐3p suppressed the migration and invasion of breast carcinoma cells through LAPTM4B by mediating epithelial‐mesenchymal transition signals, and partially reversed the carcinogenic effects of LAPTM4B by inhibiting the PI3K‐AKT‐mTOR signaling pathway. Taken together, these findings provide the first comprehensive analysis of miR‐132‐3p as a direct LAPTM4B‐targeted miRNA, and shed light on miR‐132‐3p/LAPTM4B as a significant functional axis involved in the oncogenesis and metastasis of breast cancer.

show abstract

Section: Resultsmentioning

confidence: 98%

Section: Correlation Between Laptm4b and Mir-132-3p Expression In Bmentioning

confidence: 99%

MicroRNA‐132‐3p inhibits tumor malignant progression by regulating lysosomal‐associated protein transmembrane 4 beta in breast cancer

Zhang

2019

Cancer Science

Self Cite

View full text Add to dashboard Cite

show abstract

“…Immunohistochemistry analysis of AP4 (ab28512; Abcam, Cambridge, MA, USA), LAPTM4B (bs‐6542R Bioss, Boston, MA, USA) and Ki‐67 (ZA‐0502; ZSGB‐BIO, Beijing, China) was performed in HCC tissues according to a previous description (Li et al ., ). Stained tissue sections were evaluated separately by two pathologists without any knowledge of the clinical data.…”

Section: Methodsmentioning

confidence: 97%

AP4 positively regulates LAPTM4B to promote hepatocellular carcinoma growth and metastasis, while reducing chemotherapy sensitivity

Yue

Wang

et al. 2018

Molecular Oncology

Self Cite

View full text Add to dashboard Cite

Polymorphisms of the lysosomal‐associated protein transmembrane‐4 beta (LAPTM4B) gene are related to various forms of tumour susceptibility, which led us to hypothesize that some unique transcription factors targeting this polymorphism region may affect the biological function of LAPTM4B in tumour progression. In this study, we found that the transcription factor AP4 directly binds to the polymorphism region of the LAPTM4B gene promoter and induces its transcription. In addition, we demonstrated that AP4 promotes hepatocellular carcinoma (HCC) cell proliferation and metastasis and depresses chemotherapy sensitivity via LAPTM4B by activating the PI3K/AKT signalling pathway and caspase‐dependent pathway. Interestingly, we found that AP4 could not only regulate LAPTM4B by directly binding to the promoter, but also be regulated via a positive feedback mechanism involving LAPTM4B acting on c‐myc. Finally, we showed that AP4 and LAPTM4B are highly coexpressed in HCC tissues, and their coexpression may be a marker of poor prognosis. These findings provide evidence of the expression and functional coupling between AP4 and LAPTM4B and shed light on the regulation of LAPTM4B and its function in liver cancer.

show abstract

“…BIRC5 was found to be expressed in fetal tissues and most human cancers, but absent in normal and differentiated tissues [28]. Its high expression in the primary cancer tend to associate with a poor prognosis for the patients [10,20,29]. However, the relation between high expression of BIRC5 and the prognosis of breast cancer is ambiguous, because other studies have reported it to be either irrelevant [30] or good prognosis [21].…”

Section: Discussionmentioning

confidence: 99%

“…Recently, BIRC5 has been found to be overexpressed in a variety of human tumors, such as breast cancer [10,11], lung cancer [12], hepatocellular carcinoma [13], bladder cancer [14], colorectal cancer [15,16] and prostate cancer [17]. By now, a great majority of studies [18][19][20] have shown that BIRC5 was a pejorative prognostic marker in breast cancer, but the prognostic value of BIRC5 expression in breast cancer remains controversial.…”

Section: Introductionmentioning

confidence: 99%

Performing Data Mining to Explain the Correlation between the BIRC5 Gene and Prognosis in Breast Cancer Patients

Hong

Zhāng

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Breast cancer is the most commonly malignant cancers in women, and BIRC5 has been found to be overexpressed in a variety of human tumors. Its expression is associated with the prognosis of many cancers. However, whether BIRC5 mRNA could be used as an independent prognostic factor for breast cancer remains inconsistent in previous studies.Methods: Altered BIRC5 expression in normal tissue relative to various tumor tissue and in breast cancer patients with different molecular subtypes, clinical outcomes and chemotherapy responses were examined using the Oncomine, GOBO and Kaplan-Meier plotter datasets.Results: We found that many breast cancers had increased BIRC5 mRNA expression, and GOBO analysis showed that triple-negative cell lines displayed highest BIRC5 mRNA expression levels in the breast cancer cell line panel. Moreover, BIRC5 high mRNA expression was significantly associated with longer relapse-free survival (RFS) in all breast cancer patients. In particular, sub analysis revealed that high mRNA expression of BIRC5 was significantly associated with better survival in ER positive (HR = 2.05, p = 1e-16), but not in ER negative breast cancer (HR = 1.24, p = 0.1), furthermore, the results also demonstrated that BIRC5 high expression was significantly associated with longer RFS in luminal A (HR = 1.51, p = 3.1e-06) and luminal B (HR = 1.28, p = 0.026).Conclusions: In conclusion, BIRC5 is involved in the development and progression of breast cancer and may be a suitable prognostic marker for human breast cancer.

show abstract

Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients

Cited by 39 publications

References 31 publications

MicroRNA‐132‐3p inhibits tumor malignant progression by regulating lysosomal‐associated protein transmembrane 4 beta in breast cancer

MicroRNA‐132‐3p inhibits tumor malignant progression by regulating lysosomal‐associated protein transmembrane 4 beta in breast cancer

AP4 positively regulates LAPTM4B to promote hepatocellular carcinoma growth and metastasis, while reducing chemotherapy sensitivity

Performing Data Mining to Explain the Correlation between the BIRC5 Gene and Prognosis in Breast Cancer Patients

Contact Info

Product

Resources

About